Dr. Jose Ramon Castro, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1205 Van Streat Hwy, Nicholls, GA 31554 Phone: 912-345-8979 Fax: 912-345-8970 |
News Archive
The vast majority of cells that appear to be on a one-way track to death after exposure to toxins can bounce back completely after those toxins are removed, Johns Hopkins scientists report in a new study. The finding, published in the June 15 issue of Molecular Biology of the Cell, is not only a testament to the indomitable cellular spirit, but could also offer some practical insight on how to save dying tissues after heart attacks or strokes as well as prevent cancer in cells transiently exposed to toxins.
Last year, Sally (a patient suffering from end stage liver failure) was in need of life flight transportation to be evaluated for a liver transplant. Her doctors told her she needed to receive the evaluation in order to get on the transplant list. Travel by ground ambulance or commercial flight were not an option due to her condition. Her health insurance company told her they would not cover the air ambulance medical transport. But last week, after four appeals and countless hours of work by Angel MedFlight's patient advocates, that decision was reversed.
Committing to a workout regimen at the beginning of the year may have seemed like a good idea at the time, but four months in, most of us have already lost steam. According to Jamy Ard, M.D., associate professor of epidemiology and prevention, and co-director of the Weight Management Center at Wake Forest Baptist Medical Center, that's because many of us set the bar too high.
Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its first quarter 2010 results.
GeNeuro SA, a pioneer of new therapies for neurology and autoimmune disorders, announced today that it has initiated its planned Phase IIb study "CHANGE-MS" (Clinical trial assessing the HERV-W Env ANtagonist GNbAC1 for Efficacy in Multiple Sclerosis) with its lead antibody GNbAC1 in Relapsing-Remitting Multiple Sclerosis (RRMS).
› Verified 6 days ago